CYTK - CYTOKINETICS INC

QQQ $ 472.99 $ 4.60 (0.98 %)

DIA $ 411.97 $ 2.70 (0.66 %)

SPY $ 558.49 $ 4.67 (0.84 %)

TLT $ 100.12 $ -0.47 (-0.47 %)

GLD $ 236.34 $ 4.08 (1.76 %)

Previous Close

$ 54.06

Open

$ 53.87

Bid

$ 54.09 x 254

Ask

-- x --

Day's Range

$ 53.87 - $ 55.38

52 Week Range

$ 25.98 - $ 110.25

Volume

894,410

Average Volume

Market Cap

6.36B

Beta (5Y Monthly)

$ 0.93

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-09-2024	06-30-2024	10-Q
2	05-10-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-03-2023	09-30-2023	10-Q
5	08-03-2023	06-30-2023	10-Q
6	05-05-2023	03-31-2023	10-Q
7	03-01-2023	12-31-2022	10-K
8	11-04-2022	09-30-2022	10-Q
9	08-05-2022	06-30-2022	10-Q
10	05-06-2022	03-31-2022	10-Q
11	02-25-2022	12-31-2021	10-K
12	11-05-2021	09-30-2021	10-Q
13	08-06-2021	06-30-2021	10-Q
14	05-07-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-10-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	03-04-2020	12-31-2019	10-K
20	11-01-2019	09-30-2019	10-Q
21	08-09-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-07-2019	12-31-2018	10-K
24	11-09-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-10-2018	03-31-2018	10-Q
27	03-05-2018	12-31-2017	10-K
28	11-03-2017	09-30-2017	10-Q
29	08-04-2017	06-30-2017	10-Q
30	05-04-2017	03-31-2017	10-Q
31	03-06-2017	12-31-2016	10-K
32	11-03-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-05-2016	03-31-2016	10-Q
35	03-03-2016	12-31-2015	10-K
36	11-05-2015	09-30-2015	10-Q
37	08-05-2015	06-30-2015	10-Q
38	05-04-2015	03-31-2015	10-Q
39	03-06-2015	12-31-2014	10-K
40	11-06-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-phase-1-study

Cytokinetics Sets Stage For Mid-Stage Stud...
09/09/2024 17:11:16

Cytokinetics presented positive Phase 1 trial data for CK-586, a potential heart failure treatment, showing safety, tolerabilit...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:00:53

Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:CYTK) with a Overweight.

Cytokinetics' CK-586 Advances After Phase ...
09/09/2024 11:33:52

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented...

HC Wainwright & Co. Reiterates Buy on Cyto...
09/09/2024 10:15:44

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...

Cytokinetics Announces Two Presentations A...
09/05/2024 20:18:27

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced two presentations at the 2024 American College of Clinical Pharmacolog...

JP Morgan Maintains Overweight on Cytokine...
09/05/2024 16:01:21

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $65 t...

JMP Securities Reiterates Market Outperfor...
09/04/2024 16:18:21

JMP Securities analyst Jason Butler reiterates Cytokinetics (NASDAQ:CYTK) with a Market Outperform and maintains $78 price t...

HC Wainwright & Co. Reiterates Buy on Cyto...
09/03/2024 16:17:12

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...

Needham Reiterates Buy on Cytokinetics, Ma...
09/03/2024 10:38:10

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.

Reported Earlier, Cytokinetics Presents Ne...
09/03/2024 07:27:04

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that new data related to the safety and long-term use of aficamten wer...

Goldman Sachs Downgrades Cytokinetics to N...
08/13/2024 09:13:58

Goldman Sachs analyst Paul Choi downgrades Cytokinetics (NASDAQ:CYTK) from Buy to Neutral and lowers the price target from $...

HC Wainwright & Co. Reiterates Buy on Cyto...
08/12/2024 10:10:50

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...

Needham Reiterates Buy on Cytokinetics, Ma...
08/09/2024 21:04:52

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $72 price target.

Cytokinetics Q2 2024 GAAP EPS $(1.31) Miss...
08/08/2024 20:42:41

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(1.02...

JP Morgan Maintains Overweight on Cytokine...
06/24/2024 11:56:27

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and lowers the price target from $77 t...

HC Wainwright & Co. Reiterates Buy on Cyto...
06/17/2024 14:55:09

HC Wainwright & Co. analyst Joseph Pantginis reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and maintains $90 price ta...

Cytokinetics Has Dosed The First Participa...
06/17/2024 11:32:09

peering-into-cytokineticss-recent-short-interest

Peering Into Cytokinetics's Recent Short I...
06/07/2024 16:45:14

Cytokinetics Engaged In Acquisition Talks ...
06/05/2024 14:06:21

B. Riley Securities Maintains Buy on Cytok...
06/04/2024 16:47:35

B. Riley Securities analyst Mayank Mamtani maintains Cytokinetics (NASDAQ:CYTK) with a Buy and lowers the price target from ...